Piotrowska, ZofiaZofiaPiotrowskaTan, Daniel Shao-WengDaniel Shao-WengTanSmit, Egbert FEgbert FSmitSpira, Alexander IAlexander ISpiraSoo, Ross ARoss ASooNguyen, DannyDannyNguyenLee, Victor Ho-FunVictor Ho-FunLeeCHIH-HSIN YANGVelcheti, VamsidharVamsidharVelchetiWrangle, John MJohn MWrangleSocinski, Mark AMark ASocinskiKoczywas, MariannaMariannaKoczywasJanik, John EJohn EJanikJones, JeffreyJeffreyJonesYu, Helena AlexandraHelena AlexandraYu2023-09-252023-09-252023-09-100732-183X1527-7755https://scholars.lib.ntu.edu.tw/handle/123456789/635777Although several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine scaffold leading to enhanced selectivity for EGFR ex20ins-mutant versus WT EGFR with potent inhibition of cell growth in EGFR ex20ins-positive cell lines.en[SDGs]SDG3journal article10.1200/JCO.23.00152373848482-s2.0-85170110290https://api.elsevier.com/content/abstract/scopus_id/85170110290